0.8701
price up icon17.22%   0.1278
pre-market  Vorhandelsmarkt:  .88   0.0099   +1.14%
loading

Immunic Inc Aktie (IMUX) Neueste Nachrichten

pulisher
Feb 10, 2026

Immunic showcases Phase 2 data on vidofludimus calcium at ACTRIMS Forum - Proactive financial news

Feb 10, 2026
pulisher
Feb 09, 2026

HC Wainwright Reaffirms "Buy" Rating for Immunic (NASDAQ:IMUX) - MarketBeat

Feb 09, 2026
pulisher
Feb 09, 2026

IMUX: HC Wainwright & Co. Reiterates Buy Rating with $8 Target | - GuruFocus

Feb 09, 2026
pulisher
Feb 07, 2026

Is Immunic Inc attractive for institutional investorsInsider Buying & Fast Exit Strategy with Risk Control - baoquankhu1.vn

Feb 07, 2026
pulisher
Feb 06, 2026

Brookline Cap M Predicts Immunic FY2025 Earnings - MarketBeat

Feb 06, 2026
pulisher
Feb 06, 2026

Immunic (NASDAQ:IMUX) Upgraded at Brookline Cap M - MarketBeat

Feb 06, 2026
pulisher
Feb 06, 2026

Analysts Set Expectations for Immunic FY2025 Earnings - MarketBeat

Feb 06, 2026
pulisher
Feb 06, 2026

Immunic (NASDAQ:IMUX) Upgraded at Brookline Capital Management - Defense World

Feb 06, 2026
pulisher
Feb 05, 2026

Brookline Capital Management Upgrades Immunic (NASDAQ:IMUX) to "Strong-Buy" - MarketBeat

Feb 05, 2026
pulisher
Feb 04, 2026

Immunic to present additional data on MS drug at ACTRIMS forum - Investing.com Nigeria

Feb 04, 2026
pulisher
Feb 04, 2026

Small cap wrap: Fineqia, Immunic, M2i Global, Trust Stamp… - Proactive Investors

Feb 04, 2026
pulisher
Feb 04, 2026

Immunic to present additional data on MS drug at ACTRIMS forum By Investing.com - Investing.com South Africa

Feb 04, 2026
pulisher
Feb 04, 2026

Immunic to present additional Phase 2 data on vidofludimus calcium in progressive MS - Proactive financial news

Feb 04, 2026
pulisher
Feb 04, 2026

MS trial: Immunic therapy cuts brain lesions and EBV signals - Stock Titan

Feb 04, 2026
pulisher
Feb 04, 2026

Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis - Sahm

Feb 04, 2026
pulisher
Feb 04, 2026

Buyback Watch: Is Sandisk Corporation stock a top performer YTDPortfolio Gains Report & Target Return Focused Stock Picks - baoquankhu1.vn

Feb 04, 2026
pulisher
Feb 01, 2026

Immunic, Inc. (NASDAQ:IMUX) Given Consensus Rating of "Buy" by Brokerages - MarketBeat

Feb 01, 2026
pulisher
Jan 31, 2026

Chipmakers Recap: Is Immunic Inc stock a good dividend stockJuly 2025 Reactions & Reliable Volume Spike Trade Alerts - baoquankhu1.vn

Jan 31, 2026
pulisher
Jan 31, 2026

Fed Meeting: Is Immunic Inc stock a good dividend stockWeekly Market Outlook & AI Driven Price Forecasts - baoquankhu1.vn

Jan 31, 2026
pulisher
Jan 30, 2026

Insider Traders Lose US$42k As Immunic Drops - simplywall.st

Jan 30, 2026
pulisher
Jan 29, 2026

Immunic (NASDAQ:IMUX) Trading Down 2.1%Here's Why - MarketBeat

Jan 29, 2026
pulisher
Jan 28, 2026

Published on: 2026-01-29 08:29:42 - baoquankhu1.vn

Jan 28, 2026
pulisher
Jan 28, 2026

Buy Signal: Whats next for DRTSW stockWeekly Earnings Recap & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn

Jan 28, 2026
pulisher
Jan 26, 2026

Aug Sentiment: Should value investors consider Immunic Inc2025 Earnings Surprises & Weekly High Return Stock Opportunities - baoquankhu1.vn

Jan 26, 2026
pulisher
Jan 17, 2026

Published on: 2026-01-18 02:31:06 - baoquankhu1.vn

Jan 17, 2026
pulisher
Jan 13, 2026

Market Recap: Whats next for Immunic Inc stockPortfolio Value Report & Real-Time Price Movement Reports - baoquankhu1.vn

Jan 13, 2026
pulisher
Jan 13, 2026

Valuation Update: What is Immunic Incs book value per share2025 Earnings Surprises & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn

Jan 13, 2026
pulisher
Jan 13, 2026

Aug Outlook: Can Immunic Inc stock maintain growth trajectoryEarnings Miss & Fast Gain Swing Alerts - Bộ Nội Vụ

Jan 13, 2026
pulisher
Jan 12, 2026

Immunic (IMUX) Reviews 2025 Performance and Highlights Upcoming Milestones, Shares Up 24.10% - Finviz

Jan 12, 2026
pulisher
Jan 11, 2026

Immunic targets MS market with Phase 3 dataICYMI - Proactive financial news

Jan 11, 2026
pulisher
Jan 09, 2026

Published on: 2026-01-09 20:07:43 - ulpravda.ru

Jan 09, 2026
pulisher
Jan 08, 2026

Can Immunic Inc. stock beat market expectations this quarterTrade Entry Report & AI Driven Stock Price Forecasts - Улправда

Jan 08, 2026
pulisher
Jan 08, 2026

Earnings Update: Will Immunic Inc stock see insider buyingJuly 2025 Drop Watch & Consistent Income Trade Recommendations - Bộ Nội Vụ

Jan 08, 2026
pulisher
Jan 08, 2026

How Immunic Inc. stock performs in high volatility marketsJuly 2025 Macro Moves & Weekly Hot Stock Watchlists - ulpravda.ru

Jan 08, 2026
pulisher
Jan 08, 2026

Can Immunic Inc. stock maintain operating marginsJobs Report & Consistent Profit Trade Alerts - ulpravda.ru

Jan 08, 2026
pulisher
Jan 08, 2026

Will Immunic Inc. stock see insider buyingJuly 2025 Volume & High Accuracy Investment Entry Signals - ulpravda.ru

Jan 08, 2026
pulisher
Jan 08, 2026

Why Immunic Inc. (10VA) stock appears on watchlists2025 Buyback Activity & Long-Term Growth Portfolio Plans - ulpravda.ru

Jan 08, 2026
pulisher
Jan 08, 2026

Will Immunic Inc. stock keep outperforming rivals2025 Growth vs Value & Reliable Entry Point Alerts - Улправда

Jan 08, 2026
pulisher
Jan 08, 2026

Immunic (NASDAQ:IMUX) Given Buy Rating at D. Boral Capital - Defense World

Jan 08, 2026
pulisher
Jan 07, 2026

D. Boral Capital Reaffirms Buy Rating for Immunic (NASDAQ:IMUX) - MarketBeat

Jan 07, 2026
pulisher
Jan 07, 2026

IMUX: D. Boral Capital Maintains 'Buy' Rating with $8 Price Targ - GuruFocus

Jan 07, 2026
pulisher
Jan 07, 2026

Immunic looks to 2026 data as late-stage MS program advances - Proactive financial news

Jan 07, 2026
pulisher
Jan 07, 2026

Immunic CEO on key 2025 highlights and 2026 milestones - Proactive financial news

Jan 07, 2026
pulisher
Jan 07, 2026

EQS-News: Immunic AG: Immunic Highlights 2025 Accomplishments and Upcoming Milestones - FinanzNachrichten.de

Jan 07, 2026
pulisher
Jan 07, 2026

Immunic Highlights 2025 Accomplishments and Upcoming Milestones - PR Newswire

Jan 07, 2026
pulisher
Jan 07, 2026

Immunic, Inc. (NASDAQ:IMUX) Given Consensus Rating of "Buy" by Analysts - MarketBeat

Jan 07, 2026
$44.80
price up icon 1.24%
$26.75
price down icon 0.19%
$100.75
price up icon 1.93%
$105.76
price down icon 3.31%
$146.17
price down icon 1.52%
biotechnology ONC
$346.42
price down icon 1.38%
Kapitalisierung:     |  Volumen (24h):